ESMO 2022: Pembrolizumab + Radiation Tx Not Effective for Locally Advanced Head, Neck Cancer
There was a favorable trend toward improved event-free survival, particularly in PD-L1-positive patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.